Search

Your search keyword '"Kang, Jeong Yeon"' showing total 23 results
Start Over Author "Kang, Jeong Yeon"
23 results on '"Kang, Jeong Yeon"'

4. Correction for Plaunt et al., “Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections”

Author

Plaunt, Adam J., primary, Rose, Sasha J., additional, Kang, Jeong Yeon, additional, Chen, Kuan-Ju, additional, LaSala, Daniel, additional, Heckler, Ryan P., additional, Dorfman, Arielle, additional, Smith, Barrett T., additional, Chun, Donald, additional, Viramontes, Veronica, additional, Macaluso, Antonio, additional, Li, Zhili, additional, Zhou, Yuchen, additional, Mark, Lilly, additional, Basso, Jessica, additional, Leifer, Franziska G., additional, Corboz, Michel R., additional, Chapman, Richard W., additional, Cipolla, David, additional, Perkins, Walter R., additional, Malinin, Vladimir S., additional, and Konicek, Donna M., additional

Published
2022
Full Text
View/download PDF

10. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections

Author

Plaunt, Adam J., primary, Rose, Sasha J., additional, Kang, Jeong Yeon, additional, Chen, Kuan-Ju, additional, LaSala, Daniel, additional, Heckler, Ryan P., additional, Dorfman, Arielle, additional, Smith, Barrett T., additional, Chun, Donald, additional, Viramontes, Veronica, additional, Macaluso, Antonio, additional, Li, Zhili, additional, Zhou, Yuchen, additional, Mark, Lilly, additional, Basso, Jessica, additional, Leifer, Franziska G., additional, Corboz, Michel R., additional, Chapman, Richard W., additional, Cipolla, David, additional, Perkins, Walter R., additional, Malinin, Vladimir S., additional, and Konicek, Donna M., additional

Published
2021
Full Text
View/download PDF

19. Pharmacokinetics, Antitumor and Cardioprotective Effects of Liposome-Encapsulated Phenylaminoethyl Selenide in Human Prostate Cancer Rodent Models

Author

Kang, Jeong Yeon, primary, Eggert, Mathew, additional, Mouli, Shravanthi, additional, Aljuffali, Ibrahim, additional, Fu, Xiaoyu, additional, Nie, Ben, additional, Sheil, Amy, additional, Waddey, Kendall, additional, Oldham, Charlie D., additional, May, Sheldon W., additional, Amin, Rajesh, additional, and Arnold, Robert D., additional

Published
2014
Full Text
View/download PDF

22. Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary MRSA Infections

Author

Plaunt, Adam J., Rose, Sasha J., Kang, Jeong Yeon, Chen, Kuan-Ju, LaSala, Daniel, Heckler, Ryan P., Dorfman, Arielle, Smith, Barrett T., Chun, Donald, Viramontes, Veronica, Macaluso, Antonio, Li, Zhili, Zhou, Yuchen, Mark, Lilly, Basso, Jessica, Leifer, Franziska G., Corboz, Michel R., Chapman, Richard W., Cipolla, David, Perkins, Walter R., Malinin, Vladimir S., and Konicek, Donna M.

Abstract

Chronic pulmonary MRSA disease in cystic fibrosis (CF) has a high probably of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptide therapy customized for pulmonary delivery that not only demonstrates potent activity against planktonic MRSA but also against protected colonies of MRSA both in biofilms and within cells, the latter of which have been linked to clinical antibiotic failure. A library of next-generation potent lipoglycopeptides were synthesized with an emphasis on attaining superior pharmacokinetics (PK) and pharmacodynamics to similar compounds of their class. Our strategy focused on hydrophobic modification of vancomycin where ester and amide functionality were included with carbonyl configuration and alkyl length as key variables. Candidates representative of each carbonyl attachment chemistry demonstrated potent activity in vitrowith several compounds being 30-60 times more potent than vancomycin. Several compounds were advanced into in vivonose-only inhalation PK evaluations in rats where RV94, a potent lipoglycopeptide that utilizes an inverted amide linker to attach a 10-carbon chain to vancomycin, demonstrated the most favorable lung residence time after inhalation. Further in vitroevaluation of RV94 showed superior activity to vancomycin against an expanded panel of gram-positive organisms, cellular accumulation and efficacy against intracellular MRSA, and MRSA biofilm killing. Moreover, in vivoefficacy of inhaled nebulized RV94 in a 48-h acute model of pulmonary MRSA (USA300) infection in neutropenic rats demonstrated statistically significant antibacterial activity that was superior to inhaled vancomycin.

Published
2021
Full Text
View/download PDF

23. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.

Author

Kang JY, Gao J, Shin DH, Alvarez C, Zhong W, and Kwon GS

Subjects
Acetylglucosaminidase metabolism, Amphotericin B adverse effects, Amphotericin B pharmacokinetics, Animals, Antifungal Agents adverse effects, Antifungal Agents pharmacokinetics, Area Under Curve, Chemistry, Pharmaceutical methods, Drug Administration Schedule, Male, Micelles, Polyesters chemistry, Polyethylene Glycols chemistry, Rats, Rats, Sprague-Dawley, Tissue Distribution, Amphotericin B administration & dosage, Antifungal Agents administration & dosage, Drug Carriers chemistry, Kidney drug effects
Abstract

Background: Delivery of monomeric Amphotericin B (AmB), i.e. deaggregated AmB, has been a major tactic in the reduction of renal toxicity at a membrane level, taking advantage of the selectivity of monomeric AmB for binding ergosterol over cholesterol., Objective: The aim of this study was to characterize the pharmacokinetic (PK) and renal toxicity of monomeric AmB in rats following a multiple dose regimen., Method: AmB existed primarily in a monomeric state in poly(ethylene glycol)- block -poly(N-hexyl stearate L-aspartamide) (PEG- b -PHSA) micelles (mAmB) at 2:1 ratio (mol:mol), whereas AmB as its standard formulation, Fungizone ® , was highly self-aggregated based on absorption spectroscopy., Results: After single intravenous injection, mAmB significantly (p < 0.001) increased the area under the plasma drug concentration-time curve (AUC) and reduced the volume of distribution (V d ) and total systemic clearance (CL) relative to Fungizone ® . After daily intravenous injections at dose of 1.0 mg/kg for 7 days, PK parameters of mAmB and Fungizone ® were similar to day 1. The treatment of Fungizone ® also significantly (p < 0.05) increased levels of urinary enzymes, N-acetyl-β-D-glucosaminidase (NAG) and kidney injury molecule-1 (KIM-1) by 3.1- and 3.0 fold, respectively, whereas levels of NAG and KIM-1 were unchanged for mAmB, consistent with hematoxylin and eosin (H&E) staining of excised kidneys., Conclusion: In summary, mAmB has less renal toxicity than AmB as Fungizone ® in rats after a multiple dose regimen, validating the aggregation state hypothesis of AmB in vivo ., Competing Interests: The author(s) confirm that this article content has no conflict of interest.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results